GT200600254A - Moduladores de aminoquinolina y aminoquinazolina quinasa - Google Patents

Moduladores de aminoquinolina y aminoquinazolina quinasa

Info

Publication number
GT200600254A
GT200600254A GT200600254A GT200600254A GT200600254A GT 200600254 A GT200600254 A GT 200600254A GT 200600254 A GT200600254 A GT 200600254A GT 200600254 A GT200600254 A GT 200600254A GT 200600254 A GT200600254 A GT 200600254A
Authority
GT
Guatemala
Prior art keywords
aminoquinazoline
aminoquinoline
modulators
quinasa
compounds
Prior art date
Application number
GT200600254A
Other languages
English (en)
Inventor
Nand Baindur
Michael David Gaul
Kevin Douglas Kreutter
Christian Andrew Baumann
Alexander J Kim
Guozhang Xu
Bao-Ping Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600254A publication Critical patent/GT200600254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

LA INVENCIÓN ESTÁ DIRIGIDA A COMPUESTOS AMINOQUINOLINA Y AMINOQUINAZOLINA DE FÓRMULA I, AL USO DE DICHOS COMPUESTOS COMO MODULADORES DE LA PROTEÍNA TIROSINQUINSAS, PARTICULARMENTE INHIBIDORES DE FLT3 Y/O TRKB EN UNA CÉLULA O UN SUJETO, Y AL USO DE DICHOS COMPUESTOS PARA PREVENIR O TRATAR EN UN SUJETO, UN DESORDEN Y/O DESÓRDENES PROLIFERATIVOS DE CÉLULAS RELACIONADOS CON FLT3 Y/O TRKB. LA PRESENTE INVENCIÓN ESTÁ ADEMÁS DIRIGIDA A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA PRESENTE INVENCIÓN Y A LOS MÉTODOS PARA TRATAR LOS TRASTORNOS TALES COMO CÁNCERES Y OTROS DESÓRDENES PROLIFERATIVOS DE CÉLULAS.
GT200600254A 2005-06-10 2006-06-08 Moduladores de aminoquinolina y aminoquinazolina quinasa GT200600254A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938205P 2005-06-10 2005-06-10
US74732106P 2006-05-16 2006-05-16

Publications (1)

Publication Number Publication Date
GT200600254A true GT200600254A (es) 2007-01-12

Family

ID=37101582

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600254A GT200600254A (es) 2005-06-10 2006-06-08 Moduladores de aminoquinolina y aminoquinazolina quinasa

Country Status (17)

Country Link
US (1) US20070004763A1 (es)
EP (1) EP1899319A2 (es)
JP (1) JP2008543762A (es)
KR (1) KR20080028913A (es)
AR (1) AR057062A1 (es)
AU (1) AU2006258059A1 (es)
BR (1) BRPI0611621A2 (es)
CA (1) CA2611378A1 (es)
CR (1) CR9647A (es)
EA (1) EA200800014A1 (es)
EC (1) ECSP077998A (es)
GT (1) GT200600254A (es)
IL (1) IL187685A0 (es)
NO (1) NO20080168L (es)
PE (1) PE20070113A1 (es)
TW (1) TW200716598A (es)
WO (1) WO2006135649A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039794A1 (en) * 2006-09-25 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR102537A1 (es) * 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
TW201726675A (zh) 2015-12-23 2017-08-01 默沙東藥廠 M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
US11066383B2 (en) 2016-05-04 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3496715B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018034918A1 (en) * 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
US11701371B2 (en) 2017-09-08 2023-07-18 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 inhibitors and their use for the treatment of cancer
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
BR112020026748A2 (pt) 2018-06-29 2021-03-30 Kinnate Biopharma Inc. Inibidores de quinases dependentes de ciclina
CA3106470A1 (en) 2018-07-17 2020-01-23 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
WO2020203609A1 (ja) * 2019-03-29 2020-10-08 日本ケミファ株式会社 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
CN114401955A (zh) * 2019-07-17 2022-04-26 金耐特生物制药公司 细胞周期蛋白依赖性激酶的抑制剂
JP2023535096A (ja) * 2020-07-23 2023-08-15 シトシンラボ セラピューティクス カンパニー， リミテッド キナーゼ阻害活性を有する化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT344178B (de) * 1974-07-25 1978-07-10 Pfizer Verfahren zur herstellung von neuen chinazolinverbindungen und deren saeureadditionssalzen und optisch aktiven formen
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
ES2310202T3 (es) * 2001-04-26 2009-01-01 EISAI R&D MANAGEMENT CO., LTD. Compuesto ciclico condensado que contiene nitrogeno que tiene un grupo pirazolilo como grupo sustituyente y composicion farmaceutica del mismo.
JP2005537247A (ja) * 2002-06-27 2005-12-08 シエーリング アクチエンゲゼルシャフト 置換されたキノリンｃｃｒ５受容体アンタゴニスト
PL1678166T3 (pl) * 2003-10-14 2009-12-31 Univ Arizona Inhibitory kinaz białkowych

Also Published As

Publication number Publication date
NO20080168L (no) 2008-03-07
CR9647A (es) 2008-09-09
EA200800014A1 (ru) 2008-06-30
TW200716598A (en) 2007-05-01
JP2008543762A (ja) 2008-12-04
WO2006135649A3 (en) 2007-02-15
WO2006135649A2 (en) 2006-12-21
AR057062A1 (es) 2007-11-14
EP1899319A2 (en) 2008-03-19
PE20070113A1 (es) 2007-02-09
BRPI0611621A2 (pt) 2010-09-21
ECSP077998A (es) 2008-01-23
IL187685A0 (en) 2008-08-07
KR20080028913A (ko) 2008-04-02
CA2611378A1 (en) 2006-12-21
US20070004763A1 (en) 2007-01-04
AU2006258059A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
GT200600254A (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
GT200600248A (es) Aminopirimidinas como moduladores de quinasas
SV2008002963A (es) Triazolopiridazinas como moduladores de tirosina cinasa referencia cruzada con solicitudes relacionadas ref. prd2584sv
MX341591B (es) Inhibidores de cinasa de benzoxazol y metodos de uso de los mismos.
GT200600253A (es) Aminopirimidinas como moduladores de quinasas
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
CL2008001815A1 (es) Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2013003227A1 (es) “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
BR112015023760A2 (pt) compostos e composições terapêuticas
UY29588A1 (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
UY29590A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa
CO6290655A2 (es) Inhibidors heterociclicos de estearoil-coa-desaturasa
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.